Drug Approval | April 29, 2025
IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen
This approval authorizes the company to export Ibuprofen to the Chinese markets
This approval authorizes the company to export Ibuprofen to the Chinese markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated
